Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of once-a-day triplet regimen of PTI-428, PTI-808 and PTI-801

Trial Profile

A Phase 2 study of once-a-day triplet regimen of PTI-428, PTI-808 and PTI-801

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTI 428 (Primary) ; PTI 808 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jun 2018 New trial record
    • 06 Jun 2018 According to Proteostasis Therapeutics media release, the company plans to initiate this trial by the end of the current quarter and results are expected later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top